Amarin Q4 Revenue Falls 21% to $49.2M as Net Loss Narrows to $1.2M
Amarin reported Q4 revenue of $49.2M, down 21% year-on-year, with net loss narrowing to $1.2M as operating expenses fell 31% and COGS declined 64%. The company realized $31M of targeted $70M cost savings, ended the year with $303M cash and established a long-term European license deal for VAZKEPA.
1. Q4 and Full-Year 2025 Performance
Amarin’s total net revenue for Q4 2025 was $49.2 million, a 21% decline from $62.3 million a year earlier, driven by lower rest-of-world sales and reduced U.S. net selling prices. The company narrowed its net loss to $1.2 million (2% margin) versus $48.6 million (78% margin) in Q4 2024.
2. Operational Efficiencies and Cash Strength
Amarin realized $31 million of the targeted $70 million in cost savings from its Global Restructuring Plan, incurring $37–$40 million in restructuring charges. Operating expenses fell 31% to $29.5 million and COGS declined 64%, while cash and investments rose to $302.6 million, enabling a return to positive cash flow in Q4.
3. International Commercial Strategy
The company maintained its U.S. market leadership for VASCEPA and transitioned European commercialization of VAZKEPA to a fully partnered model via a long-term license and supply agreement with Recordati S.p.A. This partnership shifts European sales to supply shipments and royalties, positioning Amarin for international growth.